ライフサイエンスコーパス: Pneumocystis pneumonia

1 major cause of respiratory impairment during Pneumocystis pneumonia.

2 umber of case reports of patients developing Pneumocystis pneumonia.

3 phages during infection using a rat model of Pneumocystis pneumonia.

4 d antibody responses before and after active Pneumocystis pneumonia.

5 ely contributes to the effect of nicotine on Pneumocystis pneumonia.

6 onic nicotine infusion blocks development of Pneumocystis pneumonia.

7 bility to an opportunistic infection such as Pneumocystis pneumonia.

8 rther promoting lung inflammation typical of Pneumocystis pneumonia.

9 odeficiency virus (HIV)-infected adults with Pneumocystis pneumonia.

10 pportunistic infections in these patients is Pneumocystis pneumonia.

11 ctions, including malaria, toxoplasmosis and Pneumocystis pneumonia.

12 uency of interstitial lung disease mimicking Pneumocystis pneumonia.

13 the most frequently diagnosed AIDS-OIs were Pneumocystis pneumonia (39.1%) and Kaposi sarcoma (20.1%

14 W3/25 also did not enhance the severity of Pneumocystis pneumonia achieved with corticosteroids alo

15 ose IL-2 therapy, two patients who developed Pneumocystis pneumonia and one patient who developed an

16 but they are less likely to be admitted for Pneumocystis pneumonia and other HIV-associated opportun

17 losis, and was largest for oral candidiasis, Pneumocystis pneumonia, and toxoplasmosis.

18 lung in CD4-deficient humans and mice during Pneumocystis pneumonia, and we have found that these CD8

19 r adjustment for known confounders and using Pneumocystis pneumonia as the referent category, mortali

20 monstrate a role for NK cells in immunity to Pneumocystis pneumonia, as well as to establish a functi

21 plays a central role in host defense against Pneumocystis pneumonia but has received only limited att

22 and used to help manage the pathogenesis of Pneumocystis pneumonia by adoptive transfer.

23 KEX1-immunized macaques were protected from Pneumocystis pneumonia, compared with mock-immunized ani

24 Pneumocystis pneumonia continues to carry significant ma

25 CD4-depleted mice with Pneumocystis pneumonia demonstrated significant mortalit

26 ents who developed and recovered from active Pneumocystis pneumonia during the study exhibited an inc

27 Previous episode of Pneumocystis pneumonia, geographic location, and age wer

28 Patients who died from Pneumocystis pneumonia had higher levels of antibody to

29 reased mortality of patients with malaria or Pneumocystis pneumonia has been linked to the appearance

30 Pneumocystis pneumonia has long been recognized as a cau

31 P may be the most common diagnosis mimicking Pneumocystis pneumonia in acquired immune deficiency syn

32 herapeutic effect in the treatment of murine Pneumocystis pneumonia in CD4-depleted mice.

33 cluding Pneumocystis jirovecii, which causes Pneumocystis pneumonia in humans, Pneumocystis carinii,

34 and provide insights into the development of Pneumocystis pneumonia in immunodeficient hosts.

35 therapeutic development in the treatment of Pneumocystis pneumonia in the immunosuppressed populatio

36 alities from opportunistic diseases, such as Pneumocystis pneumonia, in AIDS patients.

37 Pneumocystis pneumonia is a major cause of morbidity and

38 Pneumocystis pneumonia is a well-recognized lung disease

39 Respiratory failure during Pneumocystis pneumonia is mainly a consequence of exagge

40 indicate that downregulation of PU.1 during Pneumocystis pneumonia leads to decreased expression of

41 We conclude that Pneumocystis pneumonia leads to increased mortality foll

42 Patients with Pneumocystis pneumonia often develop respiratory failure

43 le of the cytokine interleukin-12 (IL-12) in Pneumocystis pneumonia or its potential use as immunothe

44 6 kg/m(2), P = .03), history of bacterial or Pneumocystis pneumonia (P = .01), and not currently taki

45 ded mean antibody levels by status at death (Pneumocystis pneumonia, P. jirovecii colonization, or ne

46 n numerous reports of clustered outbreaks of Pneumocystis pneumonia (PCP) at renal transplant centers

47 h chronic lymphocytic leukemia who died from Pneumocystis pneumonia (PCP) despite appropriate anti-Pn

48 T cells contribute to the pathophysiology of Pneumocystis pneumonia (PcP) in a murine model of AIDS-r

49 smoking correlates with reduced episodes of Pneumocystis pneumonia (PCP) in AIDS patients, we tested

50 es obtained during 113 episodes of suspected Pneumocystis pneumonia (PCP) in human immunodeficiency v

51 ocystis spp. are yeast-like fungi that cause pneumocystis pneumonia (PcP) in immunocompromised indivi

52 e, risk factors, morbidity, and mortality of Pneumocystis pneumonia (PCP) in recipients of kidney tra

53 Development of Pneumocystis pneumonia (PCP) is a common problem among i

54 Pneumocystis pneumonia (PcP) is a life-threatening infec

55 Pneumocystis pneumonia (PCP) is a major cause of morbidi

56 Pneumocystis pneumonia (PCP) is a potentially lethal opp

57 Pneumocystis pneumonia (PcP) is the most common opportun

58 Pneumocystis pneumonia (PcP) is the second leading cause

59 4; by ELISA, immunocompromised patients with Pneumocystis pneumonia (PCP) who were immunocompromised

60 i) is important in the immunopathogenesis of Pneumocystis pneumonia (PcP), but is difficult to study

61 of alveolar macrophages is decreased during Pneumocystis pneumonia (Pcp), partly because of activati

62 Pneumocystis pneumonia (PCP), the most common opportunis

63 In the mouse and rat models of Pneumocystis pneumonia (PcP), we found a distinct popula

64 tis infection but is also a key component of Pneumocystis pneumonia (PcP)-related immunopathogenesis.

65 ntly found to accumulate in the lungs during Pneumocystis pneumonia (PcP).

66 d lead to improved strategies for preventing Pneumocystis pneumonia (PCP).

67 mRNA levels were also reduced in Amo during Pneumocystis pneumonia (Pcp).

68 ges is decreased in patients or animals with Pneumocystis pneumonia (Pcp).

69 3 most common OIs among study patients were Pneumocystis pneumonia (PCP, 28%), Candida esophagitis (

70 atory fungal pathogen that causes pneumonia (Pneumocystis pneumonia [PcP]) in immunocompromised patie

71 isolates from the 18 RTRs (12 patients with Pneumocystis pneumonia [PCP], 6 colonized patients), 22

72 oxazole is considered first-line therapy for Pneumocystis pneumonia prevention in renal transplant re

73 essful in improving the uptake of first-line Pneumocystis pneumonia prophylaxis in renal transplant r

74 rospectively reviewed 119 patients receiving Pneumocystis pneumonia prophylaxis prior to and after pr

75 Pneumocystis pneumonia prophylaxis should be considered

76 Failure to take Pneumocystis pneumonia prophylaxis was associated with h

77 Pneumocystis pneumonia remains a common opportunistic in

78 a predisposing factor for the development of Pneumocystis pneumonia, specific Th mechanisms mediating

79 hniques, we demonstrated in a mouse model of Pneumocystis pneumonia that treatment with caspofungin,

80 8 T-cells are implicated in the pathology of Pneumocystis pneumonia, they did not have a role in the

81 Pneumocystis pneumonia was first diagnosed in malnourish

82 Using our murine model of Pneumocystis pneumonia, we found that loss of NK cells d

83 virus (HIV)-positive patients with presumed Pneumocystis pneumonia were analyzed to determine the sp

84 ingitis and Legionella, cytomegalovirus, and Pneumocystis pneumonias), which occurred up to 7 months

85 on the health of the rats and the levels of Pneumocystis pneumonia, which were milder than those fou

86 Prevention and treatment of Pneumocystis pneumonia with trimethoprim/sulfamethoxazol